

Date and Time: 10.15am – 4.00pm 10th February 2014

Minutes: confirmed

Guideline Development Group Meeting: Tuberculosis

Place: NICE offices
Manchester

Present: Andrew Hayward (AH) (Chair)
Sudy Anaraki (SA)
Christine Bell (CB)
Ann Chapman (AC)
Michael Eisenhut (ME)
Mango Hoto (MH)
Uday Katkar (UK)
Marc Lipman (ML)
Horace Reid (HR)
Bertie Squire (BS)

Apologies: Ibrahim Abubakar (IA)
Francis Drobniowski (FD)
Timothy Collyns (TC)
Amy McConville (AM)
Al Story (AS)

In attendance:

NICE Staff:

Emily Aidoo (EA)
Emma Banks (EB)
Stephen Duffield (SD)
Ben Doak (BD)
Jaimella Espley (JE)
Chris Gibbons (CG)
Michael Heath (MH)
Ruairaidh Hill (RH)
Lucy Hoppe (LH)
Rachel Kettle (RK)
Claire McCleod (CM)
Catherine Swann (CS)

Notes

10th February 2014

1. AH welcomed all to the 8th TB GDG meeting. AH introduced SA and UK who had recently been appointed to provide expertise to the committee with regards to communicable disease control and general practice respectively. Apologies were noted and the minutes of the last meeting were agreed as an accurate record of the previous meeting. The Chair introduced the work to be presented and discussed.
2. All GDG members were asked to share any new conflicts of interest which have not been previously declared. No conflicts of interest were declared by the group or the NICE team.
3. CS summarised Service Delivery Scoping Workshop held on 17/1 with volunteers from the GDG to explore priority areas for the service delivery recommendations. Interim methods for service delivery have already been developed by the CCP team. The service delivery group agreed that a focus on commissioning footprints and arrangements, along with consideration of centralised vs localised care were important. Key outcomes agreed by the group were reducing time to diagnosis, delivery of contact tracing, and treatment completion. CS reported that the NICE team plan to take a case study approach to the review, focusing on these issues in cities and countries that have achieved improvements. The first working meeting of the group will take place in July, and they will report back to the GDG after each meeting. Proposals for recommendations will come to the GDG for discussion and drafting prior to consultation.
4. Following feedback from the last GDG meeting LH presented a summary table bringing together information for the clinical review question asking *in people co-infected with drug susceptible, active TB and HIV receiving drug treatment for both infections, what are the key pharmacological considerations that should be taken into account when selecting a treatment regimen for treating active or latent TB*. The GDG discussed the level of detail included in the narrative and table and suggested how the information could be presented in a more visual way to clearly identify the level of interaction between drugs.
5. JE gave a presentation to the group on the NICE pathways work and how it supports the dissemination of NICE guidance and recommendations. A demonstration was given to show how this works in practice and how guidance is drawn together by topic area and relevance to help readers make sense of the guidance NICE produces. JE highlighted the structure of the NICE pathways may help the group think about the structure of this guideline update and took feedback from the group on what they considered would be useful in the guidance.
6. RK presented an overview of Public Health TB guidance PH37, noting areas of potential overlap with the current guideline update. She invited the GDG to consider and discuss how best to bring recommendations in PH37 into the current guideline, and how best to deal with overlaps. RK outlined a number of strategies for bringing existing recommendations into the guidance. The GDG worked in small groups to discuss these approaches, and reported back their conclusions to the main group.
7. AH thanked all for their attendance and input. EB highlighted that the next GDG was scheduled to be a 2 day meeting but would possibly be a 1 day meeting and the

Document 2: TB GDG8 minutes

group would be informed of this as soon as possible.

Date, time and venue of the next meeting

10am – 13th & 14th March – NICE offices, London.